630 Fifth Avenue
Suite 2260
New York, NY 10020
United States
650 812 8700
https://www.affymax.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 2
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Mark G. Thompson | CFO & Secretary | 97,49k | S.O. | 1962 |
Mr. Jonathan M. Couchman | CEO, President & Director | S.O. | S.O. | 1970 |
Dr. Tracy J. Dunn Ph.D., J.D. | Vice President of Intellectual Property & Legal Affairs | S.O. | S.O. | 1963 |
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
L’ISS Governance QualityScore de Affymax, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..